Quanterix

NASDAQ: QTRX ↗$2.99 USD~$115M (small-cap, August 2026) MCAP

#Neurology #Oncology #Immunology & Inflammation #Spatial Biology

Quanterix is a life-sciences company commercializing single-molecule array (Simoa) technology for ultra-sensitive protein biomarker detection, with platforms including the HD-X and SR-X instruments and the SP-X planar-array system. It operates in neurology, oncology, immunology, and inflammation, selling instruments, assays, and contract research services to academic, government, and pharmaceutical laboratories. Founded by David Walt in 2007 and listed on Nasdaq in 2017, the company acquired Akoya Biosciences in 2025 to add multiplexed spatial biology. In Q2 2026 it reported revenue up 34% year over year to $32.9 million while cutting its full-year 2026 revenue outlook.

Company Info

Sector:Life Sciences Tools / Precision Diagnostics

Headquarters:Billerica, Massachusetts, USA

Founded:2007

Website:www.quanterix.com/

Upcoming Milestones & Key Dates

Q3 2026

Corporate

Next quarterly financial results; commercial execution under revised 2026 outlook

Clinical Development Pipeline

Simoa HD-X platform

Target: Single-molecule array (Simoa) technology

Ultra-sensitive protein biomarker detection

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Simoa SR-X / SP-X platforms

Target: Single-molecule array (Simoa) technology

Expanded Simoa and multiplex immunoassay applications

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Everett V. Cunningham

President and Chief Executive Officer

William P. Donnelly

Executive Chair

David R. Walt, Ph.D.

Co-Founder and Chairman, Scientific Advisory Board

Careers & Job Openings

No active job listings. Check back later.